These companies' collaborations with bigger businesses validates their science -- and paves the way for future revenues and profits.
News & Analysis: Regenxbio
Here's what to look out for at the American Academy of Ophthalmology's annual meeting later this week.
Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.
RGNX earnings call for the period ending June 30, 2019.
A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
RGNX earnings call for the period ending March 31, 2019.
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
These three small-cap stocks have outstanding growth potential.
RGNX earnings call for the period ending December 31, 2018.
Roche acquired Spark Therapeutics for a cool $4.8 billion, which sent peers soaring.